One of the report authors, Dr Robert Clarke, from the ClinicalTrial Service Unit at the University of Oxford, said that the findings were "reassuring".
On Sept. 15, Rory Collins, the head of the ClinicalTrial Service Unit at Oxford, was called by Merck and told of the SEAS result, according to the letter.